| |
- IMPACT OF HIV COINFECTION ON THE AGE AND THE CAUSE OF DEATH IN PATIENTS WITH HCV CIRRHOSIS
(AASLD) Dallas, Texas
(11/30/01)
- SAFE AND POTENT SUPPRESSION OF HEPATITIS B VIRUS (HBV) WITH L-DEOXYTHYMIDINE (LDT): RESULTS OF A DOSE-ESCALATION TRIAL
(AASLD) Dallas, Texas
(11/30/01)
- EFFECT OF INTERFERON AND RIBAVIRIN ON PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH SEVERE CHRONIC HEPATITIS C.
(AASLD) Dallas, Texas
(11/30/01)
- LONG-LASTING SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C PATIENTS PREVIOUSLY TREATED WITH 40 KDA PEGINTERFERON ALFA-2A (PEGASYS)
(AASLD) Dallas, Texas
(11/30/01)
- ENHANCED VIROLOGICAL RESPONSE TO TREATMENT WITH 40 KDA PEGINTERFERON ALFA-2A (PEGASYS) IN PATIENTS PREVIOUSLY UNRESPONSIVE TO TREATMENT WITH INTERFERON ALFA-2A
(AASLD) Dallas, Texas
(11/30/01)
- Durability of Sustained Virologic response in patients with Chronic Hepatitis c after treatment With Interferon 2b Alone or in Combination with Ribavirin
(AASLD) Dallas, Texas
(11/29/01)
- Impact of Pegylated Interferon alfa-2b (Peg-Intron) and Ribavirin on Progression of Liver Fibrosis in patients with Chronic Hepatitis C
(AASLD) Dallas, Texas
(11/28/01)
- Summaries of Abstracts from the ECCATH - Meeting: Hepatitis; Interferon Monotherapy in HCV/HIV Coinfected Patients; Body Changes in Italian Women: risk factors; Drugs & the Liver; Lipodystrophy & Metabolic Abnormalities: mitochondrial toxicity & NRTIs, fat cells; Lipids & Medication Choices: the Atlantic Study; HAART and the Heart - Written for NATAP by Graeme Moyle, MD, Chelsea & Westminster Medical Center, UK, London (ECCATHI), Athens, Greece
(11/27/01)
- ACUTE HEPATITIS C: NATURAL COURSE AND RESPONSE TO ANTIVIRAL TREATMENT
(AASLD) Dallas, Texas
(11/27/01)
- Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome
(11/27/01)
- Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome
(11/27/01)
- A Randomized Study of the Utility of Human Immunodeficiency Virus RNA Measurement for the Management of Antiretroviral Therapy
(11/26/01)
- AASLD ( American Association for the Study of Liver Diseases) Conference Dallas, Texas
(11/16/01)
- Quality of Life at week 24 in Study of Pegasys + Ribavirin Compared to Standard Interferon + Ribavirin
(AASLD) Dallas, Texas
(11/13/01)
- More on the HALT-C Trial: 4-year study of Maintenance Therapy in 1350 patients Written for NATAP by Mark Sulkowski, MD, Johns Hopkins University School of Medicine
(AASLD) Dallas, Texas
(11/13/01)
- Pegylated interferon alfa/ribavirin in persons who failed to prior interferon based therapy Written for NATAP by Mark Sulkowski, MD, Johns Hopkins University School of Medicine
(AASLD) Dallas, Texas
(11/13/01)
- How Often Should You Do a Liver Biopsy?
(AASLD) Dallas, Texas&
(11/19/01)
- Hepatitis B Therapy at AASLD : Written for NATAP by Douglas T. Dieterich, MD Cabrini Hospital and NYU Medical Center, NYC
(AASLD) Dallas, Texas
(11/19/01)
- Interferon Improves Risk for Death and Cancer; New Ribavirin in Early Development; Normal ALT in African-Americans; Fats, Overweight, Diabetes in HCV; How Often Should You Do a Biopsy in HCV/HIV Coinfection
(AASLD) Dallas, Texas
(11/19/01)
- HIV/HCV Coinfection; Hispanics & HCV; Cognitive Impairment
(AASLD) Dallas, Texas
(11/19/01)
- New Hepatitis B Drugs
(AASLD) Dallas, Texas
(11/16/01)
- Preliminary Notes From Dallas AASLD Liver/hepatitis Conference:
(AASLD) Dallas, Texas
(11/16/01)
- EFFECT OF INTERFERON THERAPY ON THE RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C: A LARGE RETROSPECTIVE COHORT STUDY OF 3296 PATIENTS
(AASLD) Dallas, Texas
(11/16/01)
- Early week 24 African-Americans Response to Pegasys + Ribavirin
(AASLD) Dallas, Texas
(11/16/01)
- Care Services for HCV/HIV Coinfected
(AASLD) Dallas, Texas
(11/14/01)
- HCV Therapy Adherence; New drugs
(AASLD) Dallas, Texas
(11/14/01)
- OPEN-LABEL PHASE 1B STUDY OF HEPATITIS C VIRAL DYNAMICS WITH OMEGA INTERFERON TREATMENT
(AASLD) Dallas, Texas
(11/14/01)
- HCV Therapy in HCV/HIV Coinfection
(AASLD) Dallas, Texas
(11/14/01)
- Brief Highlights From Day 1 at AASLD, Poster Session: HCV Therapy 1
(AASLD) Dallas, Texas
(11/13/01)
- HCV Viral Load Ultrasensitive Testing
(AASLD) Dallas, Texas
(11/13/01)
- Harmless virus prevents HIV variant from spreading in human tissue blocks
(11/13/01)
- Self-reported adherence with HIV treatment correlates with viral load
(11/12/01)
- Low-impact exercise can increase bone mass in women
(11/12/01)
- Rapidly progressive HIV case highlights importance of specific immune response
(11/11/01)
- Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review
(11/11/01)
- 8th European Conference on Clinical Aspects and Treatment of HIV-Infection (ECCATHI) - Index Page - Athens, Greece
(11/8/01)
- Indinavir + Ritonavir (800/100) vs Saquinavir + Ritonavir (1000/100), both twice daily - (ECCATHI), Athens, Greece
(11/8/01)
- Hepatitis; Adverse Events(Lipodystrophy, hypersenstivity, hepatotoxicity, bone problems, Newfill for lipoatrophy, clinical studies) written by Mike Youle, MD, Royal Free Hospital, London, UK (ECCATHI), Athens, Greece
(11/8/01)
- Entry Inhibitors: T-20 (adults & children), T-1249 (early data in adults) - (ECCATHI), Athens, Greece
(11/6/01)
- Program Abstracts Presented by Tibotec/Virco at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATHI) in Athens, Greece - (ECCATHI), Athens, Greece
(11/6/01)
- Atazanavir Compared To Nelfinavir: 48 weeks - (ECCATHI), Athens, Greece
(11/03/01)
- Late phase II trial results of HIV fusion inhibitor T-20 appear promising - (ECCATHI), Athens, Greece
(11/03/01)
|
